MBX Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for MBX Biosciences (MBX).

Price Target Range — 8 Quarters

Analyst Consensus — 13 Analysts

2S.Buy

10Buy

1Sell

Consensus RatingBuy# Analysts13Avg. Consensus PT$71Upside to Avg. PT+29.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	Stifel	Annabel Samimy	PT Raise	Buy	$70→$84
Oct 2, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$88→$150
Aug 21, 2026	JP Morgan	Jessica Fye	Reinstates	Overweight	$88
Aug 10, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$70→$88
Jul 29, 2026	Mizuho	Uy Ear	PT Raise	Outperform	$57→$91
May 12, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$66→$70
May 12, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$76→$86
May 11, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$50→$70
Jan 28, 2026	Barclays	Eliana Merle	Initiate	Overweight	$66
Jan 16, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$77→$88
Jan 7, 2026	UBS	Michael Yee	Initiate	Buy	$60
Dec 19, 2025	Stifel	Annabel Samimy	PT Raise	Buy	$45→$50
Dec 4, 2025	Goldman Sachs	Corinne Johnson	Initiate	Sell	$18
Nov 10, 2025	Guggenheim	Seamus Fernandez	PT Cut	Buy	$84→$77
Nov 4, 2025	TD Cowen	Tyler Van Buren	Initiate	Buy	—
Oct 15, 2025	Truist Securities	Srikripa Devarakonda	Initiate	Buy	$50
Sep 24, 2025	Mizuho	Uy Ear	PT Raise	Outperform	$38→$56
Sep 23, 2025	Oppenheimer	Trevor Allred	PT Raise	Outperform	$38→$80
Sep 23, 2025	Guggenheim	Seamus Fernandez	PT Raise	Buy	$44→$84
Aug 15, 2025	Jefferies	Roger Song	Assumes	Buy	$36

Analyst Ratings News

PRO
Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84

Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $84.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150

Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $88 to $150.

Benzinga Newsdesk

PRO
JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target

JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88

Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91

Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $57 to $91.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70

Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises the price target from $66 to $70.

Benzinga Newsdesk

MBX Biosciences Inc

MBX Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84

PRO
Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150

PRO
JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target

PRO
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88

PRO
Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91

PRO
Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70

People Also Watch

People Also Watch

MBX Biosciences Inc

MBX Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROStifel Maintains Buy on MBX Biosciences, Raises Price Target to $84

PROGuggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150

PROJP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target

PROTruist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88

PROMizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91

PROBarclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70

People Also Watch

People Also Watch

PRO
Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84

PRO
Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150

PRO
JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target

PRO
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88

PRO
Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91

PRO
Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70